Parametrica Management Ltd Purchases Shares of 7,500 iShares Biotechnology ETF (NASDAQ:IBB)

Parametrica Management Ltd purchased a new stake in iShares Biotechnology ETF (NASDAQ:IBB) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 7,500 shares of the financial services provider’s stock, valued at approximately $1,019,000. iShares Biotechnology ETF comprises about 1.7% of Parametrica Management Ltd’s investment portfolio, making the stock its 18th largest position.

Several other hedge funds also recently added to or reduced their stakes in IBB. Jacobi Capital Management LLC grew its position in shares of iShares Biotechnology ETF by 3.7% during the third quarter. Jacobi Capital Management LLC now owns 2,539 shares of the financial services provider’s stock worth $310,000 after acquiring an additional 91 shares during the last quarter. PFG Investments LLC grew its position in shares of iShares Biotechnology ETF by 4.8% during the third quarter. PFG Investments LLC now owns 2,013 shares of the financial services provider’s stock worth $246,000 after acquiring an additional 93 shares during the last quarter. Huntington National Bank grew its position in shares of iShares Biotechnology ETF by 7.4% during the third quarter. Huntington National Bank now owns 1,450 shares of the financial services provider’s stock worth $177,000 after acquiring an additional 100 shares during the last quarter. HB Wealth Management LLC grew its position in shares of iShares Biotechnology ETF by 5.9% during the fourth quarter. HB Wealth Management LLC now owns 1,892 shares of the financial services provider’s stock worth $257,000 after acquiring an additional 105 shares during the last quarter. Finally, Peterson Wealth Management grew its position in shares of iShares Biotechnology ETF by 2.9% during the third quarter. Peterson Wealth Management now owns 3,743 shares of the financial services provider’s stock worth $458,000 after acquiring an additional 106 shares during the last quarter. 62.45% of the stock is currently owned by hedge funds and other institutional investors.

iShares Biotechnology ETF Stock Performance

NASDAQ:IBB traded up $0.82 during midday trading on Friday, reaching $126.49. The stock had a trading volume of 833,050 shares, compared to its average volume of 1,534,186. The firm has a fifty day simple moving average of $134.45 and a two-hundred day simple moving average of $129.71. iShares Biotechnology ETF has a 12-month low of $111.83 and a 12-month high of $141.16.

iShares Biotechnology ETF Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Wednesday, March 27th. Shareholders of record on Friday, March 22nd were issued a $0.126 dividend. This represents a $0.50 dividend on an annualized basis and a yield of 0.40%. The ex-dividend date was Thursday, March 21st.

iShares Biotechnology ETF Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.